Mereo BioPharma (MREO) Total Non-Current Liabilities (2017 - 2026)
Mereo BioPharma (MREO) posted quarterly Total Non-Current Liabilities of $6.2 million for Q1 2026, down 20.76% year-over-year from $7.8 million in Q1 2025, and up 42.81% quarter-over-quarter from $4.3 million in Q4 2025.
Mereo BioPharma (MREO) Total Non-Current Liabilities (2017 - 2026) Analysis & Trends
Mereo BioPharma (MREO) has reported Total Non-Current Liabilities for 10 consecutive years, with $6.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 20.76% year-over-year to $6.2 million; the TTM figure through Mar 2026 stood at $6.2 million (down 20.76% YoY), while the FY2025 annual figure was $4.3 million, down 70.27% from the prior year.
- Total Non-Current Liabilities improved to $6.2 million in Q1 2026 per MREO's latest filing, from $4.3 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $16.6 million in Q2 2024 and bottomed at $1.8 million in Q4 2022.
- Historically, Total Non-Current Liabilities has averaged $9.2 million across 5 years, with a median of $7.8 million in 2025.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities sank 94.84% — and 2023, when it soared 745.23%.
- Mereo BioPharma's Total Non-Current Liabilities stood at $1.8 million in 2022, then jumped by 745.23% to $15.2 million in 2023, then slipped by 3.93% to $14.6 million in 2024, then slumped by 70.27% to $4.3 million in 2025, then soared by 42.81% to $6.2 million in 2026.
- Business Quant data shows MREO's Total Non-Current Liabilities at $6.2 million in Q1 2026, $4.3 million in Q4 2025, and $6.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | Mereo BioPharma | 47.39 Mn | 47.39 Mn | - | 5.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.69 Mn |
| Mar 31, 2026 | 6.20 Mn |
| Dec 31, 2025 | 4.34 Mn |
| Sep 30, 2025 | 6.35 Mn |
| Jun 30, 2025 | 7.91 Mn |
| Mar 31, 2025 | 7.82 Mn |
| Dec 31, 2024 | 14.60 Mn |
| Sep 30, 2024 | 15.17 Mn |
| Jun 30, 2024 | 16.55 Mn |
| Mar 31, 2024 | 12.24 Mn |
| Dec 31, 2023 | 15.20 Mn |
| Jun 30, 2023 | 6.80 Mn |
| Dec 31, 2022 | 1.80 Mn |
| Jun 30, 2022 | 4.09 Mn |
| Dec 31, 2021 | 34.88 Mn |
| Jun 30, 2021 | 75.99 Mn |
| Dec 31, 2020 | 91.58 Mn |
| Jun 30, 2020 | 78.44 Mn |
| Dec 31, 2019 | 20.98 Mn |
| Jun 30, 2019 | 34.79 Mn |